Susceptibility to PTC596 varied in the tested AML cell lines with elevated susceptibility of the TP53 null cell line HL-60, the TP53 wild type AML cell line OCI-AML3, as well as the MDS-AML cell line MOLM-13, and reduced susceptibility of the TP53 mutant cell lines MOLM-16, SKM-1, and PL-21 as well as the TP53 wild type cell line ML-2. This evidence concerns the gene TP53 and myelodysplastic syndrome.